Back to Scientific publications

B04-furin-inhibited-car-macrophages

B04-furin-inhibited-car-macrophages

Michel Salzet, Lydia Ziane Chaouche, Marie Duhamel


WO 2025/177014 A1
https://patents.google.com/patent/WO2025177014A1/en

Abstract

Furin, a proprotein convertase, is over-expressed in human primary macrophages exposed to tumour cells and redirects them towards an anti-inflammatory, tumour-permissive phenotype. Inhibiting furin keeps CAR macrophages derived from primary blood monocytes in a pro-inflammatory state even in a tumour cell environment.

The resulting furin-inhibited CAR-M show enhanced phagocytic activity against breast cancer cell lines and patient-derived tumoroids, and their secretome enhances T-cell proliferation — a second-generation CAR-M strategy for solid tumours. Claim 1 covers the pharmaceutical composition itself.

Patent family

Publication numberOfficeKindPublished
WO 2025/177014 A1WIPOApplication2025-08-28
  • Priority date — 23 February 2024
  • Filing date — 23 February 2024
  • Status — Pending (PCT)
  • Applicants — Inserm, CHU de Lille, Université de Lille
  • Research axis — Immunotherapy & tumour targets

Context

The therapeutic vector on which WO 2026/058015 builds: the macrophage platform is protected here, the HLA-H / HLA-J targets there.

Abstract as published

CAR macrophages (CAR-M) can phagocyte tumor cells expressing a target antigen. It is herein shown that the proprotein convertase furin is over-expressed in human primary macrophages in the presence of tumor cells, which is a way to redirect these macrophages towards an anti-inflammatory phenotype. Conversely, inhibition of furin leads to the maintenance of their pro-inflammatory phenotype, even in a tumor cell environment. The present invention proposes to use furin-inhibited CAR-M derived from primary blood monocytes as a therapeutic strategy to treat solid tumors.